Table 1.

Patient demographics, pathology, PPD recurrence, synchronous or metachronous malignancies, survival, and immunophenotypes of primary perianal Paget's disease^a.

Case	Age (years)	Sex	Surgical treatment	Metachronous malignancy	PPD recurrence	Survival and follow-up	Cause of death	CK7 (7/10)	CK20 (6/10)	CDX2 (6/10)	GCDFP-15 (3/10)
1	69	M	APR	Cholangiocarcinoma (metachronous, 11 years)	None	Death, 11 years	Cholangiocarcinoma	-	+	+	-
2	83	F	WLE	None	None	Alive, 11 years	None	-	+	+	-
3	76	M	WLE	None	None	Death, 2 months	Sepsis	+	-	-	+
4	75	M	WLE	None	Yes, 1 year later	Death, 2 years	Unknown (died after discharge)	-	+	+	-
5	87	F	WLE	None	None	Death, 4 years	Respiratory failure	+	F	+	-
6	77	M	WLE	None	None	Death, 9 years	Respiratory failure	+	-	F	-
7	85	M	WLE	None	None	Death, 7 years	Unknown (died after discharge)	F	+	+	-
8	62	F	WLE	Urothelial carcinoma (metachronous, 2 years)	None	Death, 3 years	Urothelial carcinoma with multiple metastases	+	-	-	-
9	60	F	WLE then APR	None	Yes, 4 years later	Death, 6 years	DOD, PPD with lymph nodes and lung metastases	+	+	-	+
10	69	M	WLE	Rectal small-cell carcinoma (metachronous, 3 years)	None	Death, 3 years	Rectal small-cell carcinoma with lymph node metastases	+	-	-	+

^aF: focally positive. PPD: perianal Paget's disease; APR: abdominal peritoneal resection; WLE: wide local excision; DOD: died of disease.